Trials / Unknown
UnknownNCT05154604
A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-A1921 in Subjects With Advanced Malignant Solid Tumour .
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 156 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To assess the safety and tolerability of SHR-A1921 in patients with advanced solid tumours, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and/or recommended phase II dose (RP2D) of SHR-A1921
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1921 | Treatment group: Subjects will receive an intravenous infusion of SHR-A1921 in a dose escalation until confirmed progression, unaccepted toxicity, or any criterion for withdrawal from the study. |
Timeline
- Start date
- 2021-12-31
- Primary completion
- 2024-08-31
- Completion
- 2024-08-31
- First posted
- 2021-12-13
- Last updated
- 2021-12-13
Source: ClinicalTrials.gov record NCT05154604. Inclusion in this directory is not an endorsement.